Loading quotes...
Forecast
The analysts' average price target is €52.87 (+180.18%). The median is €58.80 (+211.61%).
| Buy |
32 |
| Hold |
6 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Uniqure rises after William Blair 'outperform' and progress on AMT-130
Uniqure shares gained about 2.4% in premarket trading after William Blair initiated coverage with an “Outperform” rating. Analysts are broadly optimistic (11 buy, 1 hold), and agreement with the FDA on an accelerated approval pathway for AMT-130 has boosted investor sentiment. Uniqure also benefited from a solid cash position and an amended credit facility with Hercules Capital; the recent roughly 175% rally from the 52-week low is seen as company-specific. » More on de.investing.com
uniQure receives FDA confirmation for accelerated BLA pathway for AMT-130 and reports sales increase
uniQure said the FDA confirmed in writing after a Type B meeting that a BLA filing for Huntington’s therapy AMT-130 is appropriate under an accelerated pathway based on existing clinical data. The company beat revenue consensus in Q2 with $5.84m, but reported a higher net loss per share due to increased selling, general and administrative expenses. uniQure plans to file regulatory applications in the US and the UK in Q3 2026, strengthened its balance sheet with a $259m capital raise and extended its cash runway to 2030. The announcements pushed the stock about 6.3% higher in premarket trading. » More on de.investing.com
UniQure beats revenue estimate and secures $259 million financing through 2030
UniQure reported Q2 revenue of $5.80 million, exceeding the consensus expectation of $5.47 million, while net loss widened due to higher selling, general and administrative and non‑operating expenses. The revenue increase was driven by higher license income; rising personnel and contractor costs reflect preparations for potential product launches. Through a follow‑on placement, UniQure raised $259 million and says this secures liquidity through 2030; regulatory filings for AMT‑130 are planned for Q3 2026 and topline four‑year data are expected in September 2026. » More on de.investing.com
uniQure presents mixed Phase I/IIa data on epilepsy gene therapy AMT‑260
In the low‑dose cohort (1x10^12 gc/mL) of the Phase I/IIa study, three of six patients showed a 79–100% reduction in disabling seizures in months 4–6; the other three patients had changes of −33% to +36% versus baseline. No serious adverse events have been reported to date; adverse events were mild to moderate, headaches were most common, and no immunosuppression was required. Recruitment of a higher‑dose cohort (3x10^12 gc/mL) is ongoing, with completion expected mid‑2026 and updated study data planned for H1 2027. The study announcement drove the share price up 67.9% to 46.29 USD and lifted market capitalization to 2.92 billion USD; an analysis by InvestingPro currently rates the stock as overvalued. » More on de.investing.com
UniQure to seek FDA approval for Huntington's gene therapy after agency reverses stance
UniQure plans to submit an FDA application in Q3 for its experimental gene therapy for Huntington's disease after a recent meeting indicated a three-year analysis from a Phase 1/2 study could support accelerated approval. The FDA previously questioned the sufficiency of UniQure's data and had asked for a placebo-controlled trial, but now agrees the company can use external control data and wants to align on a post-approval confirmatory study comparing the treatment to standard of care. UniQure expects to finalize the confirmatory trial design before submitting its application. » More on cnbc.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 4.59M | 45.46% |
| Gross profit | 4.38M | 55.58% |
| Net profit | -54.05M | 21.24% |
| EBITDA | -35.77M | 18.57% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.3B |
Number of shares | 70.14M |
52-week high/low | €47.15 - €7.96 |
| Dividends | No |
Beta | 0.94 |
P/E ratio | -5.73 |
PEG ratio | -0.40 |
P/B ratio | 4.82 |
P/S ratio | 70.60 |
Company profile
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Name | uniQure |
| CEO | Matthew C. Kapusta |
| Headquarters | Amsterdam,
nh Netherlands |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 02/05/2014 |
| Employees | 221 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | QURE |
London Stock Exchange | 0EE0.L |
Frankfurt | UQ1.F |
London | 0EE0.L |
SIX | UQ1.SW |